Potent CDK1/cyclin B (IC50 = 9.5 nM) and CDK2/cyclin A3 (IC50 = 5.4 nM) inhibitor. 1’000-fold more potent than NU2058. Selective for CDK1 and CDK2 compared to CDK4/D1 (IC50 = 1.6 µM), DYRK1A (IC50 = 0.9 µM), PDK1 (IC50 = 0.8 µM) and ROCK-II (IC50 = 0.6 µM). Inhibits cell growth.
More Information Supplier Page
Potent CDK1/cyclin B (IC50 = 9.5 nM) and CDK2/cyclin A3 (IC50 = 5.4 nM) inhibitor. 1’000-fold more potent than NU2058. Selective for CDK1 and CDK2 compared to CDK4/D1 (IC50 = 1.6 µM), DYRK1A (IC50 = 0.9 µM), PDK1 (IC50 = 0.8 µM) and ROCK-II (IC50 = 0.6 µM). Inhibits cell growth.
More Information Supplier Page Microtubule inhibitor. Antitumor compound. Mitosis inhibitor. Arrests the cell cycle at G2/M phase. Promotes tubulin depolymerization. Induces fragmentation of the Golgi complex. Inhibits the T cell antigen receptor. Stimulates the intrinsic GTPase activity of tubulin. Activates the JNK/SAPK signaling pathway. Apoptosis inducer. Autophagy inhibition through prevention of autophagosome-lysosome fusion.
More Information Supplier PageCell permeable, highly potent inhibitor of gamma-secretase (IC50 = 0.06 nM).
More Information Supplier PageCell permeable, highly potent inhibitor of gamma-secretase (IC50 = 0.06 nM).
More Information Supplier PagePotent and selective inhibitor of CDKs. More potent than olomoucine. Inhibits CDK1/cyclin B kinase (IC50 = 450 nM), CDK2 (IC50 = 700 nM) and CDK5/p35 (IC50 = 160 nM). Inhibits M phase promoting factor (MPF) kinase activity. Arrests human fibroblasts in G1 phase. Antitumor compound. Activates the mitogen-activated protein kinase pathway. Targets both the p53 […]
More Information Supplier PagePotent and selective inhibitor of CDKs. More potent than olomoucine. Inhibits CDK1/cyclin B kinase (IC50 = 450 nM), CDK2 (IC50 = 700 nM) and CDK5/p35 (IC50 = 160 nM). Inhibits M phase promoting factor (MPF) kinase activity. Arrests human fibroblasts in G1 phase. Antitumor compound. Activates the mitogen-activated protein kinase pathway. Targets both the p53 […]
More Information Supplier PagePotent and selective inhibitor of CDKs. More potent than olomoucine. Inhibits CDK1/cyclin B kinase (IC50 = 450 nM), CDK2 (IC50 = 700 nM) and CDK5/p35 (IC50 = 160 nM). Inhibits M phase promoting factor (MPF) kinase activity. Arrests human fibroblasts in G1 phase. Antitumor compound. Activates the mitogen-activated protein kinase pathway. Targets both the p53 […]
More Information Supplier Page
Saturated analog of sphingosine 1-phosphate (1-SP1). Ligand for sphingosine 1-phosphate (S1P/EDG) receptors. Negative control for intracellular effects of sphingosine 1-phosphate. Induces chemotaxis. Antifibrotic.
More Information Supplier Page
Saturated analog of sphingosine 1-phosphate (1-SP1). Ligand for sphingosine 1-phosphate (S1P/EDG) receptors. Negative control for intracellular effects of sphingosine 1-phosphate. Induces chemotaxis. Antifibrotic.
More Information Supplier Page 
